[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"msa---multiple-system-atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:msa---multiple-system-atrophy":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,73,105,136,182,222,250,290,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100643640","early-phase-1-test-retest-trial-with-11cmodag-005-in-pd-or-msa-and-amhc---pilot-phase-100643640","NCT07640542","Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase","An Open-label, Single-center Study to Evaluate the Safety and Test-retest Characteristics of [11C]MODAG-005 as PET Radioligand for Imaging Pathological Alpha-synuclein Deposition in the Brains of Patients With Parkinson's Disease (PD) or Multiple System Atrophy (MSA) Compared to Age-matched Healthy Controls (AMHC) - Pilot Phase","PIOSA","Inclusion Criteria:\n\n* Key inclusion criteria: Patients with MSA fulfilling both the criteria for probable MSA (Gilman et al., 2008) and clinically established MSA (Wenning et al., 2022), patients with PD fulfilling the criteria for clinically established PD (Postuma et al., 2015) or age-matched healthy controls (AMHC).\n\nExclusion Criteria:\n\n1. Laboratory tests with clinically significant abnormalities and\u002For clinically significant unstable medical illness equivalent to CTC v5.0 (common toxicity criteria) toxicities greater than grade 2.\n2. Evidence of clinically significant disease that is expected to interfere with cognitive assessments or the ability to complete the trial procedures as judged by the investigator.\n3. Clinically significant renal and hepatic dysfunction as judged by the investigator.\n4. Known hypersensitivity to the active substance or to any of the excipients of \\[11C\\]MODAG-005 solution for injection.\n5. Known hypersensitivity to the active substance or to any of the excipients in anle138b (Emrusolmin) capsules.\n6. Participant has received an investigational drug within 3 months of screening.\n7. Blood donations within 7 days before enrolment.\n8. Pregnant (see 9.1.5) or breast-feeding or having the intention of getting pregnant. Female participants of childbearing potential and male participants with female partners of childbearing potential not willing to practice effective contraception during the trial period and for 90 days following each PET\u002FCT scan.\n9. Unsuitable veins for repeated venipuncture.\n10. Contraindication to blood sampling and\u002For arterial cannulation, including but not limited to allergy to local anesthetics, peripheral vascular disease, Raynaud's phenomenon as determined by abnormal Allen's test on both arms or abnormal coagulation profile at screening. If Allen's test should be \"abnormal\" on both arms, the participant will not be eligible for arterial sampling, but will participate in the remaining assessments.\n11. MRI exclusion criteria include but not limited to: findings of cerebrovascular disease (more than two lacunar infarcts, any territorial infarct \\>1 cm\\^3, or deep white matter abnormality corresponding to an overall Fazekas scale of 3 with at least one confluent hyperintense lesion on the Fluid-Attenuated Inversion Recov ery (FLAIR) sequence that is \\>20 mm in any dimension), infectious disease, space-occupying lesions normal pressure hydrocephalus or any other abnormalities associated with central nervous system (CNS) disease. Findings that are expected to be present in the PD and MSA participants (e.g. absence of swallow tail sign, presence of regional atrophy or hot cross bun sign) do not lead to exclusion of these participants.\n12. Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI.\n13. Unwilling and\u002For unable to cooperate with trial procedures.\n\n    Exclusion criteria for age-matched healthy controls:\n14. Relevant hepatic parameters above upper limit of normal (ULN), i.e., glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), bilirubin\n15. Relevant renal parameters outside normal limits, i.e., serum creatinine and blood urea nitrogen (BUN) above ULN; urinary albumin-creatinine ratio (uACR) below lower limit of normal (LLN)\n16. Systolic blood pressure \\\u003C90 or \\>140 mmHg; diastolic blood pressure \\\u003C45 or \\>90 mmHg; heart rate \\\u003C50 or \\>95 beats per minute (BPM)",true,"50 Years","75 Years",{"count":5,"type":21},[86],"EARLY_PHASE1","This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of \\[11C\\]MODAG-005, an investigational positron emission tomography\u002Fcomputed tomography (PET\u002FCT) radioligand intended to image pathological alpha-synuclein deposition in the brain. The study will enroll participants with Parkinson's disease (PD), participants with multiple system atrophy (MSA), and age-matched healthy controls (AMHC).\n\nParticipants with PD or MSA will undergo two \\[11C\\]MODAG-005 PET\u002FCT imaging sessions: one baseline scan and one follow-up scan 7 to 48 days later. Age-matched healthy controls will undergo one baseline scan. A subset of PD and MSA participants will receive a single oral dose of anle138b (Emrusolmin) before the second scan to evaluate tracer uptake under blocking conditions. The primary objective is to assess the safety and tolerability of \\[11C\\]MODAG-005. Secondary objectives include evaluating whether \\[11C\\]MODAG-005 PET imaging can distinguish participants with MSA or PD from age-matched healthy controls, distinguish PD from MSA, and determine test-retest variability of PET outcome measures.",[89,41,90],"Parkinson Disease (PD)","Healthy Adult Participants",[92,93,94,59,95],"MODAG","MODAG GmbH","Synuclein","Lewy Body","NOT_YET_RECRUITING","2026-06-06",{"date":99,"type":64},"2026-06-10",{"date":101,"type":21},"2026-06",{"date":103,"type":21},"2027-07",{"name":93,"class":71},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100628864","invasive-home-ventilation-in-denmark-100628864","NCT07467187","Invasive Home Ventilation in Denmark","The Evolution of Invasive Home Mechanical Ventilation in Denmark","HOMEVENT DK","Inclusion Criteria:\n\n* Patients are included if they have or have had a respiratory certified personale care assistent during the period 2016-2025.\n\nExclusion Criteria:\n\n* Not tracheostomized\n* Tracheostomized but on spontaneous breathing throughout 1 January 2016 - 31 December 2025\n* Not discharged to home, assisted living, nursing home, or rehabilitation during 1 January 2016 - 31 December 2025",{"count":114,"type":21},450,"OBSERVATIONAL","The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark. This includes indications for invasive HMV, diagnostic groups, and one-year mortality.",[118,119,120,121,122,41,123,124],"Neuromuscular Diseases (NMD)","ALS (Amyotrophic Lateral Sclerosis)","Spinal Cord Injuries (SCI)","Duchenne Muscular Dystrophy (DMD)","SMA - Spinal Muscular Atrophy","Tracheostomized Patients","Tracheostomy","2026-04-15",{"date":127,"type":64},"2026-04-20",{"date":129,"type":64},"2026-04-13",{"date":131,"type":21},"2028-09-01",{"name":133,"class":134},"Rigshospitalet, Denmark","OTHER",1,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":158,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":135},"100632087","ultra-high-resolution-pet-in-aging-neurodegeneration-and-psychotic-disorders-100632087","NCT07509125","Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders","Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders","Inclusion Criteria:\n\n* WP1: Healthy controls\n* Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);\n* Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;\n* No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* In subjects \\\u003C 60 years of age, a normal structural MRI scan as assessed by expert radiologist.\n* In subjects \\>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \\\u003C= 2 (of 3) on the Age-Related White Matter changes scale are acceptable;\n* When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample.\n* WP2: Dementia\n* Patient has a clinical diagnosis of biomarker-proven prodromal AD\n* WP3: ALS spectrum\n* Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS;\n* WP4: Movement disorders\n* (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent.\n* Parkinson´s disease (PD):\n* Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32);\n* Patient has an abnormal 18F-PE2I PET;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline.\n* Multiple system atrophy (MSA)\n* Patient has clinically established or clinically probable MSA-P based on the\n* Movement Disorder Society (MDS) diagnostic criteria (33);\n* Patient has an abnormal 18F-PE2I PET.\n* Progressive supranuclear palsy (PSP)\n* Patient has an abnormal 18F-PE2I PET;\n* Patient has clinically established probable PSP according to the latest MDS criteria\n* Dementia with Lewy bodies (DLB)\n* Patient has probable DLB by consensus criteria (cognitive impairment MoCA \\\u003C 26 + visual hallucinations and\u002For fluctuating alertness);\n* Patient has an abnormal 18F-PE2I PET.\n* Idiopathic REM sleep behavior disorder (iRBD)\n* Patient has Polysomnography-confirmed iRBD;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* No clinical evidence of parkinsonism at baseline.\n* WP5: Psychosis\n* DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder;\n* Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis.\n\nExclusion Criteria:\n\n* Subject has a history of any major (other) internal, psychiatric or neurological disease that may interfere with the investigations (especially liver and kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, severe TBI);\n* Subject is currently a user (including recreational use) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse;\n* Subject chronically uses medication that has central nervous system effects (e.g. strong painkillers such as opioids, neuroleptics,..; ) (other than prescribed for the illness in case of patients);\n* Subject has had exposure to ionizing radiation (\\> 1 mSv) in other research studies within the last 12 months;\n* Subject has a contra-indication for MRI scanning;\n* Subject suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures; subject cannot lie still for (at least) 60 minutes inside the scanner;\n* (For subjects with arterial sampling): The subject is hypersensitive to lidocaine (used for local anaesthesia during the placement of the arterial catheter), has an abnormal Allen test (a test to check blood flow in the arteries of the forearm) or is on anti-coagulant therapy;\n* Subject (or his\u002Fher legal representative) does not understand the study procedures;\n* Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator;\n* Subject is potentially pregnant (hCG test can be done if doubt exists).","90 Years",{"count":145,"type":21},300,[24],"The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD), Parkinson's disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and psychotic disorders. Researchers will use the NeuroExplorer PET\u002FCT system, a new scanner that can show very small structures in the brain and spinal cord in much more detail than regular PET.\n\nThe main questions this study aims to answer are:\n\n* How do small but important brain regions (like the locus coeruleus, substantia nigra, and thalamic nuclei) change in healthy aging?\n* What early brain changes occur in neurodegenerative and psychotic disorders, and can they help improve early diagnosis?\n\nParticipants will:\n\n* Undergo PET and MRI brain scans using different tracers that measure brain metabolism (18F-FDG), synaptic density (¹⁸F-SynVesT-1), dopamine transporters (¹⁸F-PE2I), and tau protein buildup (¹⁸F-MK6240).\n* Complete cognitive and clinical assessments related to memory, mood, and motor or psychiatric symptoms, depending on their group.\n\nThis study will include healthy volunteers and patients with mild cognitive impairment due to Alzheimer´s disease, ALS, Parkinson's disease and related disorders, or psychotic disorders.\n\nThe results will help create detailed brain imaging maps for healthy aging and identify early biomarkers for different diseases to support better diagnosis and treatment in the future.",[149,150,151,152,153,41,154,155,156,157],"Alzheimer Dementia (AD)","ALS - Amyotrophic Lateral Sclerosis","Parkinson s Disease","REM Sleep Behavior Disorder (iRBD)","PSP - Progressive Supranuclear Palsy","Dementia With Lewy Bodies (DLB)","ALS With Frontotemporal Dementia (ALS\u002FFTD)","Adult Onset Psychotic Disorder","Very Late Onset Psychotic Disorder",[159,160,48,44,161,162,163,164,165,166,167,168,169,170,171,172],"PET\u002FCT scan","Alzheimer´s disease","Parkinson´s disease","REM sleep behavior disorders","Progressive supranuclear palsy","Multiple System Atrophy","Dementia with Lewy Bodies","Psychotic disorders","Schizophrenia","ALS with frontotemporal dementia","UHR PET","Locus coeruleus","Papez circuit","Thalamic subnuclei","2026-03-27",{"date":175,"type":64},"2026-04-03",{"date":177,"type":64},"2026-02-13",{"date":179,"type":21},"2029-09",{"name":181,"class":134},"Universitaire Ziekenhuizen KU Leuven",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":81,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":72},"100581157","exploring-the-olfactory-mucosa-blood-and-urine-for-the-identification-of-early-biomarkers-of-parkinsons-disease-atypical-parkinsonisms-and-neurocognitive-disorders-due-to-lewy-body-disease-100581157","NCT06846658","Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease","EXTRAORDINARY","Inclusion Criteria:\n\n* PD (Postuma et al., 2015), MSA (Palma et al., 2018), DLB (McKeith et al., 2017), OND including acquired and hereditary ataxic syndrome with known etiology, progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.\n\nExclusion Criteria:\n\n* na",{"count":190,"type":21},180,"Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages. Each disease is associated with distinct conformers of misfolded alpha-synuclein (maS) which form typical protein aggregates in the brain and represent key disease biomarkers. Thus, detection and characterization of intracerebral maS aggregates allow a definite diagnosis. The recent development of ultrasensitive assays enabled the detection of maS and other potential new biomarkers in peripheral tissues, although with several limitations. Here, the investigators propose to combine the expertise of leading and young researchers in the field of neurology, structural and molecular biology, biophysics and machine learning to perform ultrasensitive and multi-omics analyses of olfactory mucosa (OM), blood and urine of PD, MSA and DLB patients for detecting and characterizing key peripheral biomarkers allowing accurate disease recognition.",[193,41,194,195,196],"Parkinson Disease","Lewy Body Dementia (LBD)","Neurodegenerative Disease","Healthy Subjects (HS)",[198,199,200,201,202,203,204,205,206,207,208,209,210,211,212],"Parkinson's disease (PD)","multiple system atrophy (MSA)","dementia with Lewy bodies (DLB)","misfolded alpha-synuclein","new biomarkers","peripheral tissues","Real-Time Quaking-Induced Conversion (RT-QuIC)","single-molecule array (Simoa)","circulating neurofilament light chain (NfL)","Nanoparticle Tracking Analysis (NTA)","blood-derived extracellular vesicles (EVs)","multi-omics analyses","transmission electron microscopy (TEM) and protein-NMR","protein misfolding","early diagnosis","2026-03-25",{"date":215,"type":64},"2026-03-30",{"date":217,"type":64},"2023-10-03",{"date":219,"type":21},"2026-04",{"name":221,"class":134},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":135},"100628711","phase-2-autologous-stem-cell-therapy-in-patients-with-multiple-system-atrophy-100628711","NCT07465198","Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Multiple System Atrophy (MSA-P or MSA-C)\n* Age range of 35 to 65 years\n\nExclusion Criteria:\n\n* Other major neurological disorders\n* Severe cardiac\u002Frenal\u002Fhepatic impairment\n* Prior stem cell therapy","35 Years","65 Years",{"count":232,"type":21},50,[234],"PHASE2","This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo\u002Fcontrolled group.",[41,237],"MSA",[237,164,239,240],"MSC","Mesenchimal stem cells","2026-03-09",{"date":243,"type":64},"2026-03-11",{"date":245,"type":21},"2026-09-01",{"date":247,"type":21},"2031-03-01",{"name":249,"class":71},"Biocells Medical",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":81,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":258,"conditions":259,"keywords":275,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":135},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",{"count":257,"type":21},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[260,153,261,262,263,264,265,266,237,41,267,164,268,269,270,271,272,42,273,274],"PSP","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA-C","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[276,42,164,277,278,260,237,279,280],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":283,"type":64},"2026-01-14",{"date":285,"type":64},"2024-10-08",{"date":287,"type":21},"2030-12-31",{"name":289,"class":134},"Massachusetts General Hospital",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100525308","phase-2-18f-mfbg-versus-123i-mibg-and-18f-pe2i-in-pd-vs-msa-and-dlb-vs-ad-100525308","NCT06120049","[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD","Prospective Head-to-head Comparison of Cardiac [18F]-MFBG PET Versus [123I]-MIBG SPECT in the Differentiation Between Parkinson's Disease and Multiple System Atrophy and Between Dementia With Lewy Bodies and Alzheimer's Disease","Inclusion Criteria:\n\n1. Healthy Controls:\n\n   * Voluntary written informed consent.\n   * Use of highly effective methods of birth control.\n   * Age between 18 and 85 years.\n   * Good health based on medical history, physical examination, clinical laboratory tests, and urinalysis.\n   * No history or evidence of major neurological, internal, or psychiatric disorders.\n   * Normal structural MRI scan for subjects \\\u003C 60 years or minor lesions for subjects \\>= 60 years.\n2. Parkinson's Disease:\n\n   * Age 45-85 years.\n   * Clinically established PD based on Movements Disorder Society diagnostic criteria.\n   * Disease duration since onset of motor symptoms: 5 years or longer for one group and less than 5 years for another.\n   * Previous abnormal \\[18F\\]-FE-PE2I PET or \\[123I\\]-FP-CIT SPECT scan.\n   * Ability to understand the patient information brochure and provide written informed consent.\n3. Multiple System Atrophy - Parkinsonian Variant:\n\n   * Age 45-85 years.\n   * Clinically established or clinically probable MSA-P based on MDS diagnostic criteria.\n   * Previous abnormal \\[18F\\]-FE-PE2I PET or \\[123I\\]-FP-CIT SPECT scan.\n   * Ability to understand the patient information brochure and provide written informed consent.\n4. Dementia Due to Alzheimer's Disease:\n\n   * Age 50-85 years.\n   * Diagnosis of probable AD with evidence of the AD pathophysiological process.\n   * Ability to understand the patient information brochure and provide written informed consent.\n5. Dementia with Lewy Bodies:\n\n   * Age 50-85 years.\n   * Diagnosis of probable DLB.\n   * Previous abnormal \\[18F\\]-FE-PE2I PET or \\[123I\\]-FP-CIT SPECT scan.\n   * Ability to understand the patient information brochure and provide written informed consent.\n\nExclusion Criteria:\n\n1. Healthy controls:\n\n   * Major diseases that may interfere with the investigations.\n   * Evidence of cognitive impairment.\n   * History or evidence of psychiatric disease.\n   * Use of illicit drugs or history of drug or alcohol abuse.\n   * Chronic medication interfering with cardiac neuronal norepinephrine transporter (NET) or \\[18F\\]-FE-PE2I imaging.\n   * Exposure to ionizing radiation \\> 1 mSv in other research studies within the last 12 months.\n   * Contraindication for MRI scanning.\n   * Claustrophobia or inability to tolerate confinement during PET-MRI scanning.\n   * Unwillingness to avoid strenuous physical activity.\n   * Lack of understanding of the study procedures.\n   * Pregnancy or breastfeeding.\n   * Lack of agreement to communicate incidental findings to the general practitioner.\n   * Abnormal Allen test or lidocaine hypersensitivity\u002Fallergy for subjects willing to undergo arterial sampling.\n2. Parkinson's Disease:\n\n   * Neuropsychiatric diseases other than PD.\n   * Major internal medical comorbidity, especially diabetes or heart disease.\n   * White matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities.\n   * History of alcohol or drug abuse.\n   * Previous participation in research studies involving ionizing radiation.\n   * Contraindications for MR.\n   * Claustrophobia or inability to tolerate confinement during PET scanning.\n   * Unwillingness to avoid strenuous physical activity.\n   * Lack of understanding of the study procedures.\n   * Pregnancy or breastfeeding.\n   * Lack of agreement to communicate incidental findings to the general practitioner.\n   * Anticoagulant therapy.\n3. Multiple System Atrophy - Parkinsonian Variant:\n\n   * Same as for Parkinson's disease.\n4. Dementia Due to Alzheimer's Disease:\n\n   * Same as for Parkinson's disease.\n5. Dementia with Lewy Bodies:\n\n   * Same as for Parkinson's disease.","85 Years",{"count":299,"type":21},113,[234,301],"PHASE3","Study goal:\n\nThe goal of this prospective head to head comparison is to evaluate the effectiveness of \\[18F\\]-MFBG PET in assessing cardiac innervation, comparing it with \\[123I\\]-MIBG SPECT The study's primary focus is on distinguishing between Parkinson's disease (PD) and multiple system atrophy (MSA), as well as between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD).\n\nMain questions:\n\n* Feasibility: How well can \\[18F\\]-MFBG PET detect changes in myocardial uptake in PD and DLB compared to the expected normal values in healthy individuals and AD and MSA-P patients? How well can it differentiate between these groups based on the detected changes?\n* Non-inferiority: Is \\[18F\\]-MFBG PET as accurate as \\[123I\\]-MIBG SPECT in distinguishing between PD and MSA-P, and between DLB and AD?\n\nParticipant requirements:\n\nFor the main study, participants will be required to visit the hospital for 3 or 4 appointments. During these visits, they will undergo a screening visit, MRI brain scan, a comprehensive neurological assessment, \\[18F\\]-PE2I PET, \\[123I\\]-MIBG SPECT, and \\[18F\\]-MFBG PET scans.\n\nAdditionally, a separate dosimetry study will be conducted, involving healthy subjects who will visit the hospital for a screening visit and undergo \\[18F\\]-MFBG PET scans.",[193,304,41,47],"Dementia With Lewy Bodies",[193,165,41,47,306,307,308,309,310,311,312,313,314,315,316,317,318,48,319,320,321,322,323],"[18F]-MFBG","[18F]-PE2I","[123I]-MIBG","Positron emission tomography","PET","Single photon emission tomography","SPECT","Autonomic dysfunction","Cardiac innervation","Brain DAT","Dosimetry","Kinetic modelling","Differential diagnosis","Parkinsonism","Nuclear imaging","Neurology","Movement disorders","Prospective","2025-02-03",{"date":326,"type":64},"2025-02-06",{"date":328,"type":64},"2024-01-19",{"date":330,"type":21},"2026-07",{"name":332,"class":134},"prof. dr. Koen Van Laere",2,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":17,"minAge":341,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":344,"conditions":345,"keywords":350,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":135},"100224095","modifiable-variables-in-parkinsonism-mvp-100224095","NCT02194816","Modifiable Variables in Parkinsonism (MVP)","Modifiable Variables in Parkinsonism (MVP) [Formerly CAM Care in PD]","Inclusion Criteria:\n\n* Parkinson's disease (PD)\n* Parkinsonism\n* Parkinson-plus syndromes (e.g. Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBGD), Dementia with Lewy bodies)\n* Must have online access, an email address, basic computer literacy\n* Must be willing to complete online surveys every 6 months for 5 years\n\nExclusion Criteria:\n\n* Inability to read\u002Fwrite English\n* Inability or unwillingness to complete surveys every six (6) months (\\~90 min)","19 Years",{"count":343,"type":21},2000,"We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.",[346,319,41,42,347,264,304,348,349],"Parkinson's Disease","Shy-Drager Syndrome","Pick Disease","Olivopontocerebellar Atrophies",[346,351,352,353],"PD","Complementary and Alternative","CAM","2022-03-10",{"date":356,"type":64},"2022-03-25",{"date":358,"type":4},"2012-09",{"date":360,"type":21},"2030-12",{"name":362,"class":134},"Bastyr University"]